Belgium to India Pharmaceutical Import

The pharmaceutical trade corridor between Belgium and India has experienced significant growth over the past decade. In 2022, the total import value stood at $217.6 million USD, with 968 shipments from 94 Belgian suppliers to 78 Indian buyers. This robust trade relationship underscores Belgium's pivotal role in supplying pharmaceutical products to the Indian market.

Belgium has established itself as a key supplier in India's pharmaceutical import landscape. In 2022, Belgium's pharmaceutical exports to India were valued at $138.01 million USD, accounting for a substantial portion of India's total pharmaceutical imports. The primary categories imported include vaccines, antibiotics, and other essential medications, reflecting Belgium's diverse pharmaceutical offerings.

Between 2024 and 2026, the Central Drugs Standard Control Organisation (CDSCO) implemented several policy changes to streamline the import process. These included revisions to the registration procedures for foreign pharmaceutical products and updates to the guidelines for Good Manufacturing Practice (GMP) compliance. Additionally, India engaged in bilateral trade negotiations with Belgium to enhance the efficiency of pharmaceutical imports, focusing on reducing tariffs and simplifying customs procedures.

Belgian pharmaceutical companies seeking to import products into India must navigate the CDSCO registration process. This involves submitting an Integrated Registration Form (IRF) through the CDSCO's SUGAM portal, accompanied by necessary documents such as a valid address proof of the firm and an authorized person's ID proof. The application undergoes verification by CDSCO Headquarters, and upon approval, a registration certificate is issued, authorizing the import and sale of the pharmaceutical products in India.

India requires that foreign manufacturing sites adhere to Good Manufacturing Practice (GMP) standards as outlined by the World Health Organization (WHO). Belgian manufacturers must provide a GMP certificate in WHO format or a Certificate of Pharmaceutical Product (CPP) issued by the National Regulatory Authority of the country of origin. This certification ensures that the manufacturing processes meet the safety and quality standards mandated by Indian regulations.

To import pharmaceutical products into India, Belgian companies must obtain an import license (Form 10) from the CDSCO. This license is granted upon submission of a registration certificate, a No Objection Certificate (NOC), and a test license. The import process also involves compliance with customs procedures, including the submission of necessary documentation and adherence to import regulations to ensure the smooth clearance of goods at Indian ports.

The pharmaceutical imports from Belgium to India are predominantly in the vaccine category, reflecting the high demand for immunization products in India. Other significant imports include antibiotics such as clindamycin and heparin, as well as corticosteroids like prednisolone and methylprednisolone. These products are essential in treating a range of medical conditions prevalent in India, highlighting Belgium's role in supplying critical medications.

Belgium exports several innovator drugs and novel formulations to India, including biologics like daratumumab and pembrolizumab. These advanced therapies are not manufactured domestically and are crucial in the treatment of complex diseases such as cancer. The importation of these specialty products underscores the importance of international collaboration in providing cutting-edge medical treatments to the Indian population.

India's importation of pharmaceutical products from Belgium is driven by several factors, including the need for patented drugs not available domestically, technological advancements in drug manufacturing, and stringent quality requirements. The high disease burden in India necessitates access to a wide range of effective medications, making imports from Belgium a vital component of India's healthcare system.

India's import tariff structure for pharmaceutical formulations includes the Most Favored Nation (MFN) tariff rates, basic customs duty, Integrated Goods and Services Tax (IGST), and health cess. These tariffs are subject to change based on government policies and trade agreements. Importers must stay informed about the current tariff rates to ensure compliance and optimize import costs.

India and Belgium have engaged in bilateral trade negotiations to enhance the efficiency of pharmaceutical imports. These discussions focus on reducing tariffs, simplifying customs procedures, and addressing regulatory harmonization to facilitate smoother trade flows between the two countries.

India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents and ensures that only genuine innovations receive patent protection. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential drugs, including imported pharmaceuticals, to make them affordable for the Indian population. These policies impact the pricing and availability of imported drugs from Belgium.

Pharmaceutical shipments from Belgium to India primarily utilize sea routes, with major ports such as Antwerp and Zeebrugge in Belgium serving as export points. The transit time for sea shipments to Indian ports like Mumbai and Chennai typically ranges from 20 to 30 days, depending on the shipping line and specific route taken. Air freight is also utilized for time-sensitive deliveries, with transit times of approximately 7 to 10 days.

Belgium's key export ports include Antwerp and Zeebrugge, both equipped with advanced facilities to handle pharmaceutical shipments. In India, major import ports such as Mumbai, Chennai, and Kolkata are equipped with specialized infrastructure to manage pharmaceutical imports, ensuring compliance with regulatory standards and efficient processing of goods.

Indian customs procedures for pharmaceutical imports involve detailed documentation and adherence to regulatory requirements set by the CDSCO. Imported pharmaceuticals are subject to testing by the CDSCO to ensure compliance with safety and efficacy standards. Maintaining the cold chain is critical for temperature-sensitive products, and importers must ensure that their logistics partners adhere to Good Distribution Practice (GDP) guidelines to preserve product integrity throughout the supply chain.

Despite being a major pharmaceutical manufacturer, India imports a significant portion of its pharmaceutical products from Belgium due to the need for patented drugs, advanced biologics, and specialized formulations not produced domestically. This dependency highlights the importance of international trade in meeting India's diverse healthcare needs.

Major Belgian pharmaceutical companies, such as Pfizer Service Company BV and GlaxoSmithKline Biologicals SA, supply a range of products to the Indian market. These companies often engage in local partnerships and contract manufacturing to enhance their market presence and cater to the specific needs of Indian consumers.

India's Atmanirbhar Bharat initiative and the Production-Linked Incentive (PLI) scheme aim to boost domestic manufacturing capabilities, potentially reducing the reliance on pharmaceutical imports. However, the demand for specialized and patented drugs may continue to sustain imports from Belgium, albeit at a potentially reduced scale as domestic production increases.

India imports pharmaceutical products from various countries, including the USA, other EU nations, China, Switzerland, and Japan. Belgium's share in India's pharmaceutical imports is significant, but it faces competition from these countries, each offering unique products and advantages.

Belgian pharmaceutical products are favored in India due to their innovation, adherence to high-quality manufacturing standards, and strong brand reputation. The country's compliance with international regulatory standards and its focus on research and development contribute to the appeal of its products in the Indian market.

Indian manufacturers are increasingly developing alternatives to imported pharmaceuticals, including biosimilars and generic versions of patented drugs. The PLI scheme has incentivized domestic production, potentially reducing the market share for imported products. However, the complexity of certain biologics and specialized formulations may continue to necessitate imports from countries like Belgium.